NEW YORK (GenomeWeb News) — Illumina and the Mayo Clinic today said they plan to co-develop molecular diagnostics for certain undisclosed diseases, Illumina said today.
 
Under the agreement, Illumina will provide its VeraCode technology and its know-how on the BeadArray platform to Mayo Medical Laboratories, which have had the technology since January 2005.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.